TABLE 1.

Baseline characteristics of entire study cohort (n = 58)

Variable	Total cohort (n = 58)	AIH (n = 33)	ASC/PSC (n = 25)
Sex, n (%) female	25 (43%)	15 (46%)	10 (40%)
Race, n (%) White	55 (95%)	33 (100%)	22 (88%)
Age at MRI, years	16 (13, 18)	16 (13, 18)	16 (14, 17)
Duration of disease from diagnosis to MRI, months	15 (2, 39)	14 (2, 39)	16 (2, 39)
IBD diagnosis, n (%)	19 (33%)	1 (3%)*	18 (72%)*
Corticosteroid exposure, n (%)
Use at time of MRI	28 (48%)	18 (55%)	10 (40%)
Total corticosteroid exposure since diagnosis, n (%)
≥3 months	35 (60%)	19 (58%)	16 (64%)
<3 months	10 (17%)	8 (24%)	2 (8%)
None	13 (22%)	6 (18%)	7 (28%)
Weight, kg at MRI	65 (51, 75)	67 (51, 75)	63 (58, 71)
Height, cm at MRI	168 (154, 176)	165 (149, 171)*	172 (162, 180)*
BMI, kg/m2 at MRI	22 (20, 25)	23 (20, 25)	21 (19, 24)
BMI z score at MRI	0.61 (−1, 1.4)	0.7 (0.5, 1.4)*	0.3 (−0.6, 1.0)*
BUN (mg/dL)	11 (9, 12)	11 (9, 12)	10 (8, 12)
Creatinine (mg/dL)	0.6 (0.5, 0.8)	0.6 (0.5, 0.7)	0.7 (0.6, 0.8)
AST (U/L)	41 (27, 81)	47 (34, 83)	32 (24, 55)
ALT (U/L)	65 (31, 91)	68 (31, 94)	56 (34, 86)
Direct bilirubin (mg/dL)	0.2 (0.1, 0.3)	0.2 (0.1, 0.3)	0.1 (0.1, 0.3)
GGT (U/L)	55 (17, 172)	44 (15, 134)	56 (27, 202)
Albumin (g/dL)	3.8 (3.5, 4.1)	3.9 (3.6, 4.2)	3.7 (3.5, 4.1)
INR (s)	1.1 (1.1, 1.2)	1.2 (1.1, 1.2)	1.1 (1.1, 1.1)

Note: Continuous variables are expressed as median (IQR).

Abbreviations: AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ASC, autoimmune sclerosing cholangitis; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; GGT, gamma glutamyl transferase; IBD, inflammatory bowel disease; INR, international normalized ratio; IQR, interquartile range; MRI, magnetic resonance imaging; PSC, primary sclerosing cholangitis.

^*P value < .05 between the groups.